Broncho-Vaks caps. children 3.5mg 30 pc

Description

Composition
Active substance:
Lyophilisate bacterial lysates (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridians, Moraxella catarrhalis) – 3,50 mg of standardized lyophilizate OM-85 * – 20.00 mg; * Standardized OM-85 lyophilisate contains: lyophilisate bacterial lysates (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Streptococcus pyogenes, Streptococcus viridians, Moraxella catarrhalis) – 3,50 mg.
Excipients:
Pregelatinized starch – 110.00 mg Magnesium stearate – 3.00 mg Mannitol – to 200.00 mg. capsule shell: indigo – 0.01 mg titanium dioxide – 1.00 mg, gelatin – up to 50.00 mg. * Standardized OM-85 lyophilisate contains: anhydrous propyl – 0,042 mg, anhydrous sodium glutamate – 1,515 mg Mannitol – up to 20.00 mg.
Description:
Hard gelatin capsule size 3 №, cap blue opaque white opaque body. The contents of the capsule – light beige powder.
Lyophilisate bacterial lysates Haemophilus influenzae, Streptococcus pneumoniae, Streptococcus viridians, Streptococcus pyogenes, Klebsiella pneumoniae, Klebsiella ozaenae, Staphylococcus aureus, Moraxella catarrhalis), used in the preparation Broncho-Vaksom® children, is a bacterial extract containing the lyophilized fractions of the strain 21 of inactivated bacteria belonging to eight different species. Broncho-drug Vaksom® children has immunostimulatory action and enhances the immune defense of the organism against respiratory infections.
Product form:
Capsules 3.5 mg. 10 capsules in blister, 1 or 3 in the blister pack carton along with instructions for use.
Contraindications
Hypersensitivity to the active component or any of the auxiliary components of the preparation.
Dosage
3.5 mg
Indications
The drug is used for children from 6 months to 12 years old for: – the prevention of recurrent respiratory tract infections and acute exacerbation of chronic bronchitis; – complex treatment of acute respiratory tract infections.
Interaction with other drugs
The preparation can be used concurrently with other drugs used in the treatment of acute and chronic respiratory diseases. The interaction with other drugs has not yet been established.
Overdose
Information about cases no overdose. Nature Broncho-Vaksoma® children and verification of its toxicity in animals indicate that the overdose is unlikely.
pharmachologic effect
Pharmacological group:
Immunostimulatory agent.
Pharmacodynamics:
Immunobiological action: Broncho-Vaksom® children elicits an immune response lining of the digestive tract. Especially effect is manifested in Peyer’s plaques (PB) of the small intestine. Antigen-presenting cells (APCs) are activated in the BOP bacterial lysate, and subsequently stimulate the cells responsible for specific immunity. In applying the drug Broncho-Vaksom® children, an increase in the number of circulating B lymphocytes. After stimulation of B lymphocytes, an increase in the production of polyclonal antibodies, especially IgG and IgA serum secreted by the mucous membrane of respiratory tract and salivary glands. These antibodies are the first line of defense against a variety of infectious agents (bacteria and viruses). Broncho-drug Vaksom® children has a powerful stimulating action on most leukocytes, evidenced by the increase in the number of cells of the myeloid and lymphoid series, as well as a selective increase in the expression of receptors on the surface. Collectively, these data provide evidence that the drug Broncho-Vaksom® children starts biological reactions that increase immune defenses against respiratory infections. Clinically Broncho-Vaksom® children reduces the incidence of acute respiratory tract infection, reduce the duration of the flow, reduces the likelihood of acute exacerbation of chronic bronchitis, as well as increases the resistance to infections of the respiratory system. This reduces the need for use of other drugs, particularly antibiotics.
Conditions of supply of pharmacies
Without a prescription.
side effects
Broncho-Vaksom® children generally well tolerated. Most adverse reactions are related to the general category of moderate or moderately severe manifestations. The most frequent side effect is a manifestation of a disorder of the gastrointestinal tract, skin reactions, disorders of the respiratory organs.
In each particular category of side effects grouped by system-organ class and presented in decreasing order of frequency:
Very often (1/10)
Common (1/100 to 1/10)
Infrequently (from 1/1 000 to 1/100)
Rarely (from 1/10 to 1/1 000 000)
Very rarely (less than 1/10 000)
Unknown (based on available data, it is impossible to carry out an assessment)
Disorders of the gastrointestinal tract:
Common: diarrhea, abdominal pain
Unknown: vomiting, nausea
Disorders of the nervous system:
Unknown: headache.
Violations of the respiratory system, thorax mediastinum:
Common: cough
Violations of the skin and subcutaneous tissue:
Common: rash
Unknown: urticaria, angioedema
General disorders and the site of injection:
Unknown: fever, fatigue.
Violations by the immune system:
Uncommon: hypersensitivity (rash erythematous, rash generalized, erythema, edema, eyelid edema, facial edema, peripheral edema, swelling, swelling of the face, itching, generalized itching, shortness of breath).
special instructions
To prevent overdosing children should not use the drug from the capsule intended for adults (adult Broncho-Vaksom® capsule 7 mg). Components of the drug can cause hypersensitivity reaction. In the case of conserved gastrointestinal disorders, skin reactions, disorders of the respiratory system or other symptoms of intolerance to the preparation, treatment should be discontinued because these symptoms are a manifestation of allergic reactions. Broncho-Vaksom® children should not be used in children under the age of 6 months.
Effect on the ability to drive mechanisms and
Broncho-Vaksom® children does not affect the ability to drive and use machines.
Storage conditions
Store at a temperature of from 15 to 25 C.
Keep out of the reach of children.
Dosing and Administration
For the treatment of acute or exacerbation of chronic respiratory infections: one capsule drug Broncho-Vaksom® children daily on an empty stomach until symptoms disappear, at least 10 days. When the need for antibiotic therapy Broncho-Vaksom® children should be taken in conjunction with an antibiotic from the beginning of treatment. The duration of treatment should be determined by a physician based on the individual patient’s condition. For the prevention of relapse and maintenance treatment: one capsule drug Broncho-Vaksom® children every morning on an empty stomach. The treatment consists of three cycles, each consisting of one capsule daily administration for 10 days, the interval between cycles of 20 days. Children under 3 years of age or if it is difficult to swallow the capsule child, it should be opened and the contents mixed with a drink (water, fruit juice, milk, etc).
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist